Fluconazole

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Deep Mycosis

Conditions

Deep Mycosis

Trial Timeline

Nov 1, 2012 → Oct 1, 2014

NCT ID

NCT01680458

About Fluconazole

Fluconazole is a pre-clinical stage product being developed by Pfizer for Deep Mycosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01680458. Target conditions include Deep Mycosis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00002077	Pre-clinical	Completed	—	—	Meningitis, Cryptococcal
NCT00002306	Pre-clinical	Completed	—	—	Meningitis, Cryptococcal
NCT00000627	Pre-clinical	Completed	—	Nov 1, 1994	HIV Infections
NCT00002040	Pre-clinical	Completed	—	—	Meningitis, Cryptococcal
NCT00002010	Pre-clinical	Completed	—	—	Meningitis
NCT00002325	Pre-clinical	Completed	—	—	Mycoses
NCT00000744	Pre-clinical	Completed	—	Dec 1, 1995	Candidiasis
NCT00002339	Phase 3	Completed	—	—	Candidiasis, Esophageal
NCT00002038	Pre-clinical	Completed	—	—	Candidiasis
NCT00002294	Pre-clinical	Completed	—	—	Meningitis, Cryptococcal
NCT00002076	Pre-clinical	Completed	—	—	Meningitis, Cryptococcal
NCT01806623	Phase 3	Completed	Mar 5, 2013	Nov 22, 2013	Vulvovaginal Candidiasis
NCT01680458	Pre-clinical	Completed	Nov 1, 2012	Oct 1, 2014	Deep Mycosis
NCT00645242	Phase 3	Completed	Nov 1, 2002	Mar 1, 2003	Tinea Capitis

Competing Products

20 competing products in Deep Mycosis

See all competitors

Product	Company	Stage	Hype Score
Edoxaban low dose + Edoxaban high dose	Daiichi Sankyo	Phase 1	33
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarin	Daiichi Sankyo	Phase 2	52
Fragmin (dalteparin sodium )	Pfizer	Pre-clinical	22
Dalteparin sodium injection + Warfarin	Pfizer	Approved	84
Low Molecular Weight Heparin (dalteparin)	Pfizer	Approved	84
Apixaban + Unfractionated Heparin (UFH) + Warfarin	Pfizer	Phase 3	76
Apixaban	Pfizer	Approved	84
Apixaban	Bristol Myers Squibb	Phase 2	51
Enoxaparin + Placebo + Apixaban + Placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Apixaban	Bristol Myers Squibb	Pre-clinical	22
Enoxaparin + Apixaban + Enoxaparin-matching placebo + Apixaban-matching placebo	Bristol Myers Squibb	Phase 3	76
Enoxaparin	Sanofi	Pre-clinical	22
Clexane	Sanofi	Approved	84
Idrabiotaparinux sodium + Idraparinux sodium + Avidin + Placebo (for Avidin)	Sanofi	Phase 3	76
SanOrg34006 + LMW heparin + Unfractionated heparin + Vitamin K antagonist (VKA)	Sanofi	Phase 3	76
Rivaroxaban (Xarelto, BAY59-7939) + Standard of care	Bayer	Pre-clinical	20
Rivaroxaban (Xarelto, BAY59-7939) + Rivaroxaban (Xarelto, BAY59-7939) + Unfractionated heparin + Warfarin	Bayer	Phase 3	74
Rivaroxaban (Xarelto, BAY59-7939) + Recommended VTE pharmacological treatments according to international guidelines	Bayer	Pre-clinical	20
Triptorelin Acetate 3.75mg intramuscular injection	Ipsen	Pre-clinical	20

Other Products from Pfizer